Centessa Pharmaceuticals plc (CNTA) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
10.24
↑+195% vs avg
5yr avg: 3.48
30Y Low0.9·High6.4
ROE
↑
-42.6%
↓+43% vs avg
5yr avg: -75.2%
30Y Low-344%·High-43%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CNTA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Centessa Pharmaceuticals plc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $6.2B | $3.4B | $1.9B | $766M | $290M | $1.0B | — |
| Enterprise Value | $6.1B | $3.3B | $1.7B | $722M | $-34302410 | $494M | — |
| P/E Ratio → | -27.24 | — | — | — | — | — | — |
| P/S Ratio | 410.24 | 226.28 | — | 111.71 | — | — | — |
| P/B Ratio | 10.24 | 6.44 | 4.78 | 3.24 | 0.86 | 2.06 | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CNTA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 222.70 | — | 105.38 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
CNTA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Centessa Pharmaceuticals plc earns an operating margin of -1384.6%. Operating margins have expanded from -2499.4% to -1384.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -42.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | 100.0% | — | — | — |
| Operating Margin | -1384.6% | -1384.6% | — | -2499.4% | — | — | — |
| Net Profit Margin | -1316.9% | -1316.9% | — | -2204.7% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -42.6% | -42.6% | -73.9% | -52.8% | -52.2% | -154.4% | -344.2% |
| ROA | -31.2% | -31.2% | -50.3% | -37.6% | -40.3% | -119.1% | -91.0% |
| ROIC | -51.2% | -51.2% | -91.8% | -125.3% | -1291.7% | — | — |
| ROCE | -35.7% | -35.7% | -47.9% | -47.1% | -42.0% | -123.3% | -337.0% |
CNTA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $61M exceeds total debt of $8M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.29 | 0.36 | 0.21 | 0.15 | 1.82 |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.10 | -0.66 | -0.18 | -0.96 | -1.06 | -0.52 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -18.12 | -18.12 | -22.08 | -16.78 | -28.81 | -54.67 | -27.21 |
Net cash position: cash ($61M) exceeds total debt ($8M)
CNTA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Centessa Pharmaceuticals plc's current ratio of 8.57x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 8.00x to 8.57x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 8.57 | 8.57 | 9.25 | 8.00 | 11.42 | 25.52 | 1.30 |
| Quick Ratio | 8.57 | 8.57 | 9.25 | 8.00 | 11.42 | 25.52 | 1.30 |
| Cash Ratio | 6.86 | 6.86 | 8.31 | 6.51 | 10.27 | 24.15 | 0.84 |
| Asset Turnover | — | 0.02 | — | 0.02 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 2085.08 | — | — | — |
CNTA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Centessa Pharmaceuticals plc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $136M | $114M | $96M | $93M | $90M | $71M |
Peer Comparison
Compare CNTA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CNTAYou | $6B | -27.2 | — | — | 100.0% | -1384.6% | -42.6% | -51.2% | — |
 KYMR | $7B | -22.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 ARQT | $3B | -189.2 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 PRAX | $7B | -18.4 | — | — | — | — | -45.8% | -65.0% | — |
 VERA | $2B | -7.2 | — | — | — | — | -50.7% | -54.6% | — |
 TPST | $6M | -0.2 | — | — | — | — | -203.6% | -352.0% | — |
 ALNY | $39B | 124.2 | 68.6 | 83.0 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 PTGX | $7B | -53.6 | — | 125.9 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 XENE | $4B | -12.0 | — | — | 66.1% | -4974.3% | -51.8% | -55.3% | — |
 ACAD | $4B | 9.3 | 25.5 | 34.8 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
What if you invested $1,000 in CNTA 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in CNTA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs CNTA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCNTA vs KYMR — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Kymera Therapeutics, Inc..
Compare NowCNTA — Frequently Asked Questions
Quick answers to the most common questions about buying CNTA stock.
What is Centessa Pharmaceuticals plc's P/E ratio?
Centessa Pharmaceuticals plc's current P/E ratio is -27.2x. This places it at the 50th percentile of its historical range.
What is Centessa Pharmaceuticals plc's ROE?
Centessa Pharmaceuticals plc's return on equity (ROE) is -42.6%. The historical average is -120.0%.
Is CNTA stock overvalued?
Based on historical data, Centessa Pharmaceuticals plc is trading at a P/E of -27.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Centessa Pharmaceuticals plc's profit margins?
Centessa Pharmaceuticals plc has 100.0% gross margin and -1384.6% operating margin.